Production of human monoclonal and polyclonal antibodies in TransChromo animals.
about
Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleasesHuman antibody production in transgenic animalsHigh-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH regionAnti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cellsAntibodies as therapeutic agents: vive la renaissance!Mining human antibody repertoires.TransChromo Mouse.Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymomaHuman antibodies from transgenic animals.Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Antibodies against G-protein coupled receptors: novel uses in screening and drug development.Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.Smarter drugs: a focus on pan-specific monoclonal antibodies.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicryThe trans-chromosomic mouse-derived human monoclonal antibody promotes phagocytosis of Porphyromonas gingivalis by neutrophils.Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.Phage display-derived human antibodies in clinical development and therapyCharacterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM.MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model.Targeted disruption of the porcine immunoglobulin kappa light chain locus.Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.The r40-kDa outer membrane protein human monoclonal antibody protects against Porphyromonas gingivalis-induced bone loss in rats.Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
P2860
Q21089956-86FDFC6B-A12E-4F5A-8629-101A86A08F36Q27023477-F1CFDBA6-CAF6-4939-91EE-EB601FAD1B55Q28709119-4F7917A1-0252-4992-889D-8E022A2EE5A5Q28732763-A0CDB0A7-D5BB-41C9-A646-FAA4E43FDB09Q33193524-6E4DAB1B-F4A6-4284-B0A2-627DE109E015Q33588489-42517822-C4A5-4368-B312-FA5F0ED72FBFQ35042465-68F4385B-C3B9-46CC-B815-FA7D5BB11065Q35959307-6E97C87A-5F8A-4591-96D3-07C4DB0D4A18Q36214596-01812588-703F-482B-8B3E-084D934882E4Q36252986-7C9B63BC-5CB9-4384-9694-6E8D671C33A5Q36363294-98B8D522-D44E-44FA-887E-B649B594A7BDQ37012681-686FFE9C-C120-4D18-914F-97D17EB96DBAQ37233054-D6F6BBF0-8011-472B-9894-D3BD7526100EQ37452067-5C021BEB-B77E-47FC-896B-AAFCB128E243Q37952285-7D769021-CE2A-43D1-935E-1916C76E4288Q38365426-490E51F0-D9C1-4F2E-B22B-5D3926FBA79CQ38811508-B914CAB2-1A1B-46C0-B6F8-35634A3194E9Q40146896-52ECB658-B695-4BC3-AA69-B986B8D760BAQ40353620-6127E9A8-0E08-450E-8BDD-69F7258876C2Q40421358-9DCC763C-3509-4FED-86F2-E59DB66AB030Q40623393-8090124F-9165-489B-9C27-475DB83AEBACQ41242816-62867C0F-F911-4031-8795-99D3D61D4BB3Q41416393-30B3685E-A67F-4A68-B2E1-DE6DA1A1A8A6Q41824131-867D1CDB-CC9C-4AEA-865A-C9F202F7C3A9Q42082214-AA58A8BB-48ED-49CB-AF77-9CA160B86336Q42408410-1019120A-BF63-422A-A4F6-4EAFD0DC72CEQ52603890-6CFB658E-1EF6-43A5-9780-BEF9DA80A491Q52877939-B1E524C5-71C2-47C6-ADCA-A11E1022F8C1Q53556406-69F021E4-AB66-4E48-9CF8-2B73117EC704Q55552584-4CC5A746-7BB8-4B5A-A800-8C8F5B53C37F
P2860
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@ast
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@en
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@nl
type
label
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@ast
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@en
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@nl
prefLabel
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@ast
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@en
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@nl
P2093
P1476
Production of human monoclonal and polyclonal antibodies in TransChromo animals.
@en
P2093
Atsuko Ohguma
Chikateru Nozaki
Hiroaki Maeda
Hitoshi Yoshida
Isao Ishida
Kazuma Tomizuka
Misako Umehashi
Nils Lonberg
Nobuaki Takahashi
P304
P356
10.1089/153623002753632084
P577
2002-01-01T00:00:00Z